Plus   Neg

Stock Alert: Zogenix Shares Up 17% In Early Trade On FDA Approval For Fintepla

Shares of Zogenix Inc. (ZGNX) are rising over 17% in pre-market today, after the pharmaceutical company announced that the U.S. FDA has approved FINTEPLA oral solution, CIV for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older.

FINTEPLA would be launched through a restricted distribution program, called the FINTEPLA Risk Evaluation and Mitigation Strategy or REMS Program, and is expected to be available through Zogenix's specialty pharmacy partner by the end of July.

The stock has been trading in the range of $16.65 - $57.22 for the past one year, and closed Thursday's trade at $28.12, down 25 cents or 0.88%. ZGNX is currently trading at $32.99, up $4.87 or 17.32% in the pre-market session.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Follow RTT